Please assess the completion status of the following clinical trial:

Trial Title: Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females aged ≥ 18 and ≤ 70 years~2. Detectable Hepatitis C Virus ribonucleic acid (HCV-RNA) in serum~3. HCV genotype 1 infection~4. Child-Pugh-Turcotte (CPT) score \< 7 and Model for End-Stage Liver Disease (MELD) score \< 18~5. PegIFN alfa-2a/RBV-naïve or previously treated patients (partial responders, null responders and relapsers)~6. Hepatocellular carcinoma within transplant criteria in the United Network for Organ Sharing (UNOS) Region IV:~   1. Single lesion up to 6 cm, or~  2. Two or three lesions with largest no greater than 5 cm and the total tumor diameter no greater than 9 cm~7. Listed for liver transplantation~8. Willingness to give written consent and agree to double contraception~Exclusion Criteria:~1. Decompensated cirrhosis~2. Baseline platelet count less than 35,000/µL~3. Baseline hemoglobin level less than 10 g/dL~4. Baseline absolute neutrophil count less than 750/mm3~5. Baseline creatinine clearance \< 50 mL per min.~6. Women with a positive pregnancy test at baseline or men whose female partners are pregnant or are contemplating pregnancy~7. Intolerance or contraindications to PegIFN alfa-2a/RBV use per standard treatment guidelines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir (Type: EXPERIMENTAL): Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (\< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).